Citius Phase 1 Trial Shows 27% Response Rate with LYMPHIR ...

Clinical trial demonstrates promising 27% response rate and 57-week progression-free survival in gynecological cancers, with potential to ...

Citius' LYMPHIR Shows Potential To Boost Pembrolizumab Efficacy

Citius shares promising results from ongoing Phase I clinical trial evaluating KEYTRUDA in combination with LYMPHIR in patients with ...

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc ... - PR Newswire

("Citius Oncology") (Nasdaq: CTOR), today announced promising preliminary results from an ongoing investigator-initiated Phase I clinical trial ...

Merck's Keytruda and Citius' Lymphir combo trial shows promising ...

Merck's Keytruda and Citius' Lymphir combo trial shows promising results. ... A clinical-stage precision oncology company focused on the treatment ...

Pembrolizumab Plus Denileukin Diftitox Shows Promise in Solid ...

A phase 1 trial of pembrolizumab plus denileukin diftitox shows 27% response and 33% clinical benefit in recurrent solid tumors, ...

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Annou...

... Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer ... Citius Phase 1 Trial Shows 27% Response Rate with LYMPHIR-Keytruda ...

Denileukin Diftitox Combo Shows Promising ORR and CBR in Solid ...

Data presented at the 2024 Society for Immunotherapy of Cancer Annual Meeting (SITC) showed that the objective response rate (ORR) was 27% (n = ...

Phase I Clinical Trial of Pembrolizumab + and Denileukin diftitox in ...

An overall response rate (ORR) of 27% (4/15) and a clinical benefit rate of 33% (5/15) among evaluable patients; and,; Median progression ...

Citius Pharmaceuticals (CTXR) and Citius Oncology (CTOR) Report ...

Citius Pharmaceuticals (CTXR) and Citius Oncology (CTOR) Report Prelim Results of an Investigator-Initiated Phase I Clinical Trial of ...

FDA Approves Citius Pharmaceuticals' Lymphir for Relapsed or ...

Efficacy results found a complete response rate of 9% and a partial response rate of 27%. Additionally, the results found an overall response ...

Citius Pharmaceuticals Resubmits BLA to Address Product Testing ...

There were no safety or efficacy issues identified in the FDA complete response letter for Lymphir, with no additional trials required.

FDA Approves Citius' Lymphir for T-Cell Lymphoma

The FDA's approval was based on favorable outcomes from a late-stage clinical trial, where Lymphir achieved an objective response rate of 36.2% ...

Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage ...

A decision on the LYMPHIR BLA is expected on August 13, 2024, the FDA's assigned Prescription Drug User Fee Act (PDUFA) action date. If approved ...

T-DXd Sequencing and Treatment Options in the Tumor-Agnostic ...

Data presented at the 2024 Society for Immunotherapy of Cancer Annual Meeting (SITC) showed that the objective response rate (ORR) was 27% (n = ...

Lymphir Approved for Relapsed or Refractory Cutaneous T-Cell ...

Findings showed an objective response rate (primary endpoint) of 36.2% (95% CI, 25.0-48.7%); 8.7% of patients had a complete response. The ...

FDA Accepts BLA Resubmission of Denileukin Diftitox for R/R CTCL

Citius pharmaceuticals reports topline data from the pivotal phase 3 study of cancer immunotherapy I ... response rate (CRR) of 88% (n = 22).

Pipeline - Clinical Trials & Publications - Citius Pharmaceuticals, Inc.

The second phase to the pivotal trial was a 70-patient study administered at the 9 mcg/kg/dose rate for 5 consecutive days in 21-day cycles, The inclusion ...

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights ...

LYMPHIR is indicated for the treatment of adult patients with relapsed or refractory Stage I-. III cutaneous T-cell lymphoma (CTCL) after at least one prior ...

FDA Approves Denileukin Diftitox-cxdl (Lymphir) for R/R Cutaneous ...

The study's primary endpoint was objective response rate (ORR), which was assessed by an independent review committee. The ORR was 36.2% (95 ...

Citius Pharmaceuticals Resubmits BLA to FDA for Lymphir to Treat ...

Pivotal Phase III Study 302 trial data show an objective response rate of 36.2% based on an independent review committee assessment in the ...